MedTrace Logo

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

NCT06760208 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 660

Last updated 2026-03-12

No results posted yet for this study

Summary

The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.

This study is seeking for participants who are:

* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed Prevenar 20 by their physician as per approved product label

All participants in this study will receive Prevenar 20 vaccine.

1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.

We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.

Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.

Conditions

  • Pneumococcal Immunization
  • Safety

Interventions

BIOLOGICAL

Pneumococcal 20-valent conjugate vaccine

For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be administered intramuscularly, preferably in the deltoid muscle, with care to avoid injection into or near nerves and blood vessels.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
6 Weeks
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-13
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06760208 on ClinicalTrials.gov